GMP cell banking provides a reproducible starting point for production. Biologics manufacturing begins with a controlled, well-characterized cell source. GMP analytics confirms the identity, purity, stability and microbiological quality of cell banks throughout their lifecycle and supports process consistency.
Understanding GMP Cell Banking and Its Quality Requirements
GMP cell banking preserves a defined cell population for clinical and commercial manufacturing. Host cell line is fundamental to product quality for biologics manufacturing. The cell banking objective is to establish a qualified starting material.
ICH Q5D describes a two-tier system based on a master cell bank (MCB) and working cell bank (WCB) as a generally accepted approach. The MCB serves as the primary reference source and is used to generate WCBs for manufacturing. This limits repeated expansion of the MCB and helps maintain a consistent starting point across production campaigns. MCB is defined as an aliquot of a single pool of cells that generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers, and stored under defined conditions.
Specifically with the impact of the field of cell banks, the following areas should be subject to guidance and harmonisation:
Stay ahead of the geopolitical week.
MD Briefing delivers expert analysis across five global fronts — the Indo-Pacific, energy, geoeconomics, European security, and the Middle East — every Monday morning. Free.
- Expression vectors authorized for iPSC generation
- Minimum identity testing
- Minimum purity testing (including adventitious agent testing)
- Stability testing
Quality requirements also include traceability of the host cell line, development history and biological materials. Storage and handling controls should reduce risks of mix-ups, contamination and loss of viability.
Establishing and Characterizing Master and Working Cell Banks
The master cell bank is normally established from a selected production clone or defined precursor bank. Its purpose is to preserve the production cell substrate at an early, controlled stage. The working cell bank is generated from the MCB and provides cells for routine manufacturing. Expectations depend on product type and development phase. For biological investigational products in the EU, an MCB should generally be established before Phase I trials, while a WCB may not always be required at that stage.
To characterize a cell line, necessary analyses must be performed. Test results can be used to make decisions and plan the method and duration of the study. The most important issue in this section is selecting the appropriate method and correctly performing the desired test.
| Cell Banking Stage | Critical Quality Attribute |
| Cell Line Selection | Identity testing (PCR, NGS, STR profiling, isoenzyme analysis) |
| Cell Expansion | Cell doubling time, Viability, Sterility (Mycoplasma, Endotoxin), Phenotype markers |
| MCB Creation | Karyotyping, Viral testing, Tumorgenicity (if applicable) |
| WCB Creation | Sterility, Potency, Cell-specific functionality assays |
| Cell Bank Release | Batch consistency, Post-thaw recovery, Contamination clearance |
Tab. 1. MCB/WCB Characteristics.
Cell bank characterization should demonstrate that cells correspond to the intended cell line and remain suitable for production. Manufacturers should also evaluate whether relevant characteristics remain stable through the cultivation period used in production. ICH Q5D links characterization with stability testing during cultivation and assessment of cells at or beyond the proposed production limit.
How GMP Analytics Supports Cell Bank Identity Purity and Stability?
GMP analytics provides evidence that the cell bank is correctly identified, sufficiently pure and capable of supporting a consistent process.
Identity testing may use genetic methods, species-specific assays or phenotypic markers. Complementary techniques strengthen confidence that the bank has not been misidentified or cross-contaminated.
Purity testing addresses microbiological and biological risks. Cell bank quality control may include sterility-related testing, mycoplasma testing and assessment for adventitious agents. Viral safety is particularly important for mammalian, avian and insect systems. ICH Q5A(R2) recognizes that viral contamination can originate from the cell-line source, biological raw materials, reagents, cell banking activities or later manufacturing steps.
Cell bank stability is broader than frozen storage time. It also concerns whether cells recover after thawing and retain relevant characteristics through the generations required for manufacturing.
Analytical Testing for Contamination and Cell Bank Consistency
Contamination testing is a critical element of cell bank characterization. The strategy should reflect cell origin, materials used during development, platform-specific risks and regulatory expectations. Because no single assay detects every potential contaminant, complementary methods are typically required.
Microbiological testing remains essential in cell bank analysis. Using molecular techniques allows for the sensitive detection of specific pathogens. Mycoplasma testing is particularly important because contamination can occur without visible visual changes. Depending on the cell substrate and the results of the risk assessment, it is necessary to consider parameters for final evaluation by analytical methods.
Another parameter that should also be monitored is cell bank stability. This is determined by assessing the viability, growth potential, productivity, and expression stability of cells after thawing. These changes can impact process efficiency, especially when a single MCB serves multiple WCBs and long-term GMP-compliant production of biologics.
Maintaining GMP Compliance Throughout the Cell Bank Lifecycle
GMP cell banking does not end when a bank is released. Lifecycle control includes qualified storage, temperature monitoring, controlled access, inventory management, documented vial retrieval and procedures for deviations or excursions. In the EU, storage sites for master and working cell banks are also relevant in regulatory documentation.
Change control is equally important. A new WCB, storage relocation, modified analytical method or change to critical materials may require impact assessment and, when justified, additional qualification or comparability testing.
The strongest GMP cell banking programs integrate cell line development, GMP analytics, quality assurance and manufacturing. A partner that connects cell bank characterization, contamination testing and GMP manufacturing can reduce handovers and identify risks earlier.
Ultimately, cell bank quality control is not only a regulatory requirement. It is a key element of process consistency, manufacturing reliability and long-term control of biologics production.
